van der Pol, Simon http://orcid.org/0000-0003-1784-1001
Rojas Garcia, Paula
Antoñanzas Villar, Fernando
Postma, Maarten J.
van Asselt, Antoinette D. I.
Funding for this research was provided by:
innovative medicines initiative (820755)
Article History
Accepted: 10 October 2021
First Online: 1 November 2021
Declarations
:
: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited. This paper reflects the authors’ views only, not that of the funder or supporting organisations.
: Professor Maarten J<i>.</i> Postma received grants and honoraria from various pharmaceutical companies all unrelated to this research, except those underlying the IMI EU VALUE-Dx project underlying this work. Simon van der Pol, Paula Rojas Garcia, Fernando Antoñanzas Villar, and Antoinette D.I. van Asselt have no conflicts of interest to declare.
: All authors contributed to the study conception and design. The first draft of the manuscript was written by SvdP and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.